Synaptogenix (SNPX) Competitors $3.74 -0.27 (-6.63%) As of 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. MIRA, QTTB, BLRX, OVID, GELS, LGVN, SNYR, NXTC, DRRX, and CLRBShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include MIRA Pharmaceuticals (MIRA), Q32 Bio (QTTB), BioLineRx (BLRX), Ovid Therapeutics (OVID), Gelteq (GELS), Longeveron (LGVN), Synergy CHC (SNYR), NextCure (NXTC), DURECT (DRRX), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors MIRA Pharmaceuticals Q32 Bio BioLineRx Ovid Therapeutics Gelteq Longeveron Synergy CHC NextCure DURECT Cellectar Biosciences Synaptogenix (NASDAQ:SNPX) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk. Which has stronger valuation & earnings, SNPX or MIRA? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynaptogenixN/AN/A-$12.77M-$10.08-0.37MIRA PharmaceuticalsN/AN/A-$7.85M-$0.51-2.44 Does the media prefer SNPX or MIRA? In the previous week, Synaptogenix and Synaptogenix both had 1 articles in the media. Synaptogenix's average media sentiment score of 0.00 equaled MIRA Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MIRA Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, SNPX or MIRA? Synaptogenix has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, MIRA Pharmaceuticals has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Is SNPX or MIRA more profitable? Synaptogenix's return on equity of -115.28% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets SynaptogenixN/A -115.28% -58.31% MIRA Pharmaceuticals N/A -341.08%-272.93% Do institutionals and insiders believe in SNPX or MIRA? 10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend SNPX or MIRA? Synaptogenix currently has a consensus price target of $14.00, indicating a potential upside of 274.83%. MIRA Pharmaceuticals has a consensus price target of $14.00, indicating a potential upside of 1,023.60%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 SummaryMIRA Pharmaceuticals beats Synaptogenix on 9 of the 12 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.19M$2.81B$5.21B$8.73BDividend YieldN/A2.72%5.38%4.23%P/E Ratio-0.3721.1825.1419.41Price / SalesN/A291.85395.78117.11Price / CashN/A42.0435.5255.95Price / Book0.867.328.005.48Net Income-$12.77M-$55.19M$3.15B$248.27M7 Day Performance-8.90%1.03%0.85%0.83%1 Month Performance67.11%8.27%5.18%4.53%1 Year Performance-13.74%-0.55%37.45%17.20% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenix1.674 of 5 stars$3.74-6.6%$14.00+274.8%-10.5%$5.19MN/A-0.374News CoverageGap DownMIRAMIRA Pharmaceuticals2.4484 of 5 stars$1.28+2.4%$14.00+993.8%+81.7%$20.47MN/A-2.512News CoverageQTTBQ32 Bio2.8709 of 5 stars$1.62-3.6%$12.17+651.0%-89.7%$20.37M$1.16M-0.3339News CoverageBLRXBioLineRx2.659 of 5 stars$4.42-5.4%$26.00+488.2%-81.8%$19.99M$28.94M-0.5040Gap UpOVIDOvid Therapeutics4.5688 of 5 stars$0.30+4.1%$2.78+820.4%-61.8%$19.92M$570K-0.8660News CoverageGap UpGELSGelteqN/A$1.84-3.7%N/AN/A$19.82M$100K0.00N/AGap UpLGVNLongeveron3.6687 of 5 stars$1.22-5.4%$8.67+610.4%-35.4%$19.41M$2.39M-0.1920News CoverageGap UpSNYRSynergy CHC3.7925 of 5 stars$2.17-5.2%$10.00+360.8%N/A$19.12M$34.83M0.0040Positive NewsHigh Trading VolumeNXTCNextCure4.3246 of 5 stars$0.45-10.1%$3.50+675.2%-72.3%$19.10MN/A-0.2690News CoverageHigh Trading VolumeDRRXDURECT0.6088 of 5 stars$0.64+0.6%N/A-56.7%$19.09M$2.03M-4.2480Gap DownCLRBCellectar Biosciences2.7363 of 5 stars$0.35-8.1%$12.50+3,457.2%-88.7%$19.04MN/A-0.4810News CoverageGap Down Related Companies and Tools Related Companies MIRA Pharmaceuticals Alternatives Q32 Bio Alternatives BioLineRx Alternatives Ovid Therapeutics Alternatives Gelteq Alternatives Longeveron Alternatives Synergy CHC Alternatives NextCure Alternatives DURECT Alternatives Cellectar Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNPX Stock Free SNPX Stock Alerts